Skip to main content
. 2018 Sep 6;7:22. doi: 10.1186/s40164-018-0114-9

Fig. 1.

Fig. 1

Disposition of patients as randomized: distribution of randomized patients into three arms (the proposed pegfilgrastim biosimilar, US-licensed pegfilgrastim reference product, an EU-approved pegfilgrastim reference product), including the number of patients that withdrew and completed treatment and safety follow up